SCHEMBL1663654

SCHEMBL1663654

O=C(O)c1ccc(N2CCC(CO)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.66
KDM4E B2RXH2 1/20 0.54
HRH1 P35367 1/20 0.49
CCR3 P51677 1/20 0.49
KCNH2 Q12809 1/20 0.49
ENPP2 Q13822 2/20 0.46
EPHX2 P34913 1/20 0.46
ALDH1A1 P00352 3/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
RORC P51449 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
STAT1 P42224 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22692236 0.90 USP2 (0.58) USP2KDM4EHRH1CCR3KCNH2
SCHEMBL20046250 0.90 USP2 (0.58) USP2KDM4EHRH1CCR3KCNH2
SCHEMBL1663774 0.87 USP2 (0.62) USP2KDM4EHRH1CCR3KCNH2
SCHEMBL23051536 0.85 USP2 (0.69) USP2KDM4EHRH1CCR3KCNH2
SCHEMBL25141511 0.83 USP2 (0.51) USP2KDM4EENPP2ALDH1A1TSHR
SCHEMBL7911517 0.83 USP2 (0.65) USP2KDM4EHRH1CCR3KCNH2
SCHEMBL23051641 0.83 USP2 (0.69) USP2KDM4EHRH1CCR3KCNH2
Terephthalic Acid SCHEMBL31485057 0.82 TSHR (0.55) USP2ALDH1A1TSHRTP53ALOX15
Terephthalic Acid SCHEMBL87786 0.82 TSHR (0.55) USP2ALDH1A1TSHRTP53ALOX15
SCHEMBL1663461 0.81 USP2 (0.51) USP2KDM4EALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070277-A Androgen receptor PROTAC 葛兰素史密斯克莱知识产权发展有限公司 2026-05-19 CN disclosed
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 US disclosed
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 US disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 US disclosed
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US disclosed
US-12441708-B2 Cereblon ligands and bifunctional compounds comprising the same ARVINAS OPERATIONS, INC. (US) 2025-10-14 US disclosed
US-20250313547-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-10-09 US disclosed
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-09-30 US disclosed
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 US disclosed
WO-2025108406-A1 HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR, AND USE THEREOF 广东东阳光药业股份有限公司 2025-05-30 WO disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
EP-2642994-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS Ligand Pharmaceuticals Incorporated (US) 2013-10-02 EP disclosed
CN-103282034-A Use of hematopoietic growth factor mimetics LIGAND PHARM INC 2013-09-04 CN disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
WO-2008053131-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 USP2 34/4885KDM4E 1613/4885HRH1 3728/4885
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE H1-2, HDAC1, H1-0 USP2 1492/4885KDM4E 650/4885HRH1 135/4885
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL USP2 3509/4885KDM4E 3484/4885HRH1 1833/4885
US-20250313547-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 USP2 34/4885KDM4E 1613/4885HRH1 3728/4885
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 USP2 3169/4885KDM4E 2201/4885HRH1 3711/4885
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 USP2 263/4885KDM4E 1417/4885HRH1 3550/4885
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 USP2 276/4885KDM4E 1036/4885HRH1 2470/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF USP2 3851/4885KDM4E 1944/4885HRH1 1466/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 USP2 276/4885KDM4E 1036/4885HRH1 2470/4885
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR USP2 92/4885KDM4E 886/4885HRH1 2282/4885
US-12441708-B2 Cereblon ligands and bifunctional compounds comprising the same CRBN, CBL, MDM2 USP2 34/4885KDM4E 1613/4885HRH1 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.